As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals

Nicole DeFeudis

Editor

BioNTech’s Covid-19 vaccine took center stage at the company’s Q1 call with investors on Monday — and though execs saw sales triple last quarter, they’re also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Roche’s Parkinson’s drug flunks second mid-stage trial

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Exclusive: Can oral antibodies work? A small startup thinks it has an answer

As BioN­Tech pre­dicts a drop in its moth­er lode of Covid sales, ex­ecs hint at com­ing M&A deals

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Ex­clu­sive: Can oral an­ti­bod­ies work? A small start­up thinks it has an an­swer

As BioNTech predicts a drop in its mother lode of Covid sales, execs hint at coming M&A deals

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Roche’s Parkinson’s drug flunks second mid-stage trial

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Exclusive: Can oral antibodies work? A small startup thinks it has an answer